Heart failure with preserved ejection fraction: The impact of stricter definitions

European Journal of Heart Failure

Volumn 16, Issue 7, 2014, Pages 767-771

  Patel, Hitesh C ^a   Hayward, Carl ^a   Di Mario, Carlo ^a   Cowie, Martin R ^a,b   Lyon, Alexander R ^a,b   Rosen, Stuart D ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Clinical trials; Diastolic dysfunction; Heart Failure; Renal denervation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEASIBILITY STUDY; GENERAL HOSPITAL; HEART ATRIUM ENLARGEMENT; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TEACHING HOSPITAL; UNITED KINGDOM; BLOOD; ECHOGRAPHY; FEMALE; HEART FAILURE; HEART FAILURE, DIASTOLIC; HEART STROKE VOLUME; HEART VENTRICLE; HEART VENTRICLE REMODELING; MALE; PATIENT SELECTION; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; HEART FAILURE; HEART FAILURE, DIASTOLIC; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; RETROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 84903769517     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.106     Document Type: Article

References (20)

1. Yamamoto K, Origasa H, Hori M,. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-118.
2. Edelmann F, Wachter R, Schmidt A, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen H, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B,. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
3. Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G, LeWinter M, Rouleau J, Bull D, Mann D, Deswal A, Stevenson L, Givertz M, Ofili E, O'Connor C, Felker M, Goldsmith S, Bart B, McNulty S, Ibarra J, Lin G, Oh J, Patel M, Kim R, Tracy R, Velazquez E, Anstrom K, Hernandez A, Mascette A, Braunwald E,. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomised clinical trial. JAMA 2013; 309: 1268-1277.
4. Paulus W, van Ballegoij J,. Treatment of heart failure with normal ejection fraction. An inconvenient truth!. J Am Coll Cardiol 2010; 55: 526-537.
5. Massie B, Carson P, McMurray J, Komajda M, McKelvie ZM, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A,. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
6. Verloop W, Beeftink M, Nap A, Bots M, Velthuis B, Appelman Y, Cramer M, Agema W, Scholtens A, Doevendans P, Allaart C, Voskuil M,. Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial. Eur J Heart Fail 2013; 15: 1429-1437.
7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
8. West R, Liang L, Fonarow G, Kociol R, Mill R, O'Connor C, Hernandez A,. Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail 2011; 13: 945-952.
9. Cleland J, Dargie H, Hardman S, McDonagh T, Mitchell P,. National Heart Failure Audit. April 2012-March 2013. http://www.ucl.ac.uk/nicor/nicor/NHFAreport2013
10. Khand A, Shaw M, Gemmel I, Cleland J,. Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure. Eur J Heart Fail 2005; 7: 792-797. (Pubitemid 41125895)
11. Mahadevean G, Dwivedi G, Williams L, Steeds R, Frenneaux M,. Epidemiology and diagnosis of heart failure with preserved left ventricular ejection fraction: rationale and design of the study. Eur J Heart Fail 2011; 14: 106-112.
12. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M,. Enright PL; Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001; 87: 413-419.
13. Lam C, Roger V, Rodeheffer R, Borlaug B, Enders F, Redfield M,. Pulmonary hypertension in heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 53: 1119-1126.
14. Redfield M, Jacobsen S, Burnett J, Mahoney D, Bailey K, Rodeheffer R,. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202. (Pubitemid 36068707)
15. Cleland J, Taylor J, Freemantle N, Goode K, Rigby A, Tendera M,. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail 2012; 14: 487-494.
16. Dahlstrom U,. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004; 6: 284-287.
17. Cleland J, Pellicori P,. Defining diastolic heart failure and identifying effective therapies. JAMA 2013; 309: 825-826.
18. Shah A, Shah S, Anand I, Sweitzer N, O'Meara E, Heitner J, Sopko G, Li G, Assmann S, McKinlay S, Pitt B, Pfeffer M, Solomon S,. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014; 7: 104-115.
19. Ho C, Solomon S,. A clinician's guide to tissue doppler imaging. Circulation 2006; 113: e396-e398. (Pubitemid 43739460)
20. Paulus W, Tschope C, Sanderson J, Rusconi C, Flachskampf F, Rademakers F, Marino P, Smiseth O, de Keulenaer G, Leite-Moreira A, Borbely A, Edes I, Handoko M, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser A, Brutsaert D,. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 20: 2539-2550. (Pubitemid 47614269)